Results 251 to 260 of about 165,965 (304)

GLP-1 Receptor Agonists

The Diabetes Educator, 2015
Purpose Type 2 diabetes (T2D) imparts an increased risk of adverse health outcomes in patients unable to achieve glycemic control. Patient education and individualization of treatment are important for effective management of T2D.
Curtis, Triplitt, Carolina, Solis-Herrera   +1 more
openaire   +2 more sources

GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension.

JAMA Neurology
Importance Current treatment options for idiopathic intracranial hypertension (IIH) are limited by efficacy, safety, and sustainability concerns. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs), known for promoting weight loss and metabolic ...
G. Sioutas, W. Mualem, J. Reavey-Cantwell, Dennis J. Rivet   +3 more
semanticscholar   +1 more source

Novel GLP-1 receptor agonists for diabetes

Expert Opinion on Investigational Drugs, 2011
GLP-1 receptor agonists have been shown to be effective in the treatment of type 2 diabetes mellitus (T2DM). Although the first GLP-1 receptor agonist, exenatide, was approved in the mid-2000s, other agents with longer durations of action (that do not require twice-daily dosing) are now being developed.
openaire   +2 more sources

Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions.

The Lancet Gastroenterology and Hepatology
The availability of glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) such as liraglutide and semaglutide, and a GLP-1 and glucose dependent insulinotropic polypeptide coagonist (tirzepatide) represents a paradigm shift in the management of both ...
R. Jalleh, Christopher K. Rayner, Trygve Hausken, K. Jones, Michael Camilleri, Michael Horowitz   +5 more
semanticscholar   +1 more source

Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide

Journal of Clinical Endocrinology and Metabolism
Context Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are established therapeutics for type 2 diabetes and obesity. Among other mechanisms, they slow gastric emptying and motility of the small intestine.
R. Jalleh, M. Plummer, C. Marathe, M. Umapathysivam, D. Quast, Christopher K. Rayner, K. Jones, Tongzhi Wu, M. Horowitz, Michael A. Nauck   +9 more
semanticscholar   +1 more source

GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

JAMA Internal Medicine
IMPORTANCE: Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasing cause of cirrhosis. Glucagon-like peptide-1 receptor agonists (GLP-1RA) are effective in improving liver inflammation in patients with MASLD.
F. Kanwal, Jennifer R Kramer, Liang Li, Yu-Xiao Yang, Yumei Cao, Xian Yu, Ronald E. Samuel, Basim Ali, Roxanne Desiderio, G. Cholankeril, Mandeep Bajaj, H. El‐Serag, Steven M. Asch   +12 more
semanticscholar   +1 more source

GLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: a retrospective cohort study

The Lancet Diabetes and Endocrinology
Summary Background Given the cardiovascular, renal, and survival benefits of GLP-1 receptor agonists for diabetes, these agents could be effective among kidney transplant recipients.
B. Orandi, Yu-Syuan Chen, Yiting Li, Garyn T. Metoyer, Krista L. Lentine, M. Weintraub, S. Bae, Nicole M Ali, B. Lonze, C. Ren-Fielding, Holly Lofton, Akash Gujral, D. Segev, M. McAdams‐DeMarco   +13 more
semanticscholar   +1 more source

The potential role of GLP‐1 receptor agonists in osteoarthritis

Pharmacotherapy
Osteoarthritis (OA) is the most common form of arthritis, affecting over 500 million people globally. Current treatments are primarily symptom‐focused, with no approved therapies to halt disease progression. Glucagon‐like peptide‐1 receptor agonists (GLP‐
Mackenzie Ryan, Saige Megyeri, W. Nuffer, Jennifer M. Trujillo   +3 more
semanticscholar   +1 more source

Perioperative management of long-acting glucagon-like peptide-1 (GLP-1) receptor agonists: concerns for delayed gastric emptying and pulmonary aspiration.

British Journal of Anaesthesia
Prescriptions and use of glucagon-like peptide-1 (GLP-1) receptor agonists are increasing dramatically, as indications are expanding from the treatment of diabetes mellitus to weight loss for people with obesity.
M. L. van Zuylen, S. Siegelaar, M. Plummer, Adam M. Deane, J. Hermanides, A. Hulst   +5 more
semanticscholar   +1 more source

Albiglutide: a unique GLP-1 receptor agonist

Expert Opinion on Biological Therapy, 2016
Albiglutide is a long acting GLP-1 receptor agonist (GLP-1 RA) administered by weekly injection. Area covered: The pharmacokinetic and pharmacodynamic properties of albiglutide and its clinical effects are discussed. The review encompassed a search of PubMed and a thorough analysis of the European Union and US Food and Drug Administration approval ...
openaire   +2 more sources